Bifogade filer
PDF
Kurs
+31,94%
Likviditet
0,70 MSEK
Kalender
| Est. tid* | ||
| 2025-08-22 | 15:20 | Kvartalsrapport 2025-Q2 |
| 2025-06-03 | N/A | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2025-06-02 | N/A | Årsstämma |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-11-15 | - | 15-10 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-05 | - | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2024-06-04 | - | Årsstämma |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-09 | - | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2023-06-08 | - | Årsstämma |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-02 | - | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2022-06-01 | - | Årsstämma |
| 2022-05-17 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-14 | - | Extra Bolagsstämma 2022 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-12-30 | - | Extra Bolagsstämma 2021 |
| 2021-11-23 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-23 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-02 | - | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2021-06-01 | - | Årsstämma |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-05 | - | Bokslutskommuniké 2020 |
| 2020-11-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-06 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-17 | - | X-dag ordinarie utdelning S2M 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-03-06 | - | Bokslutskommuniké 2018 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
An independent study published in the Journal of Plastic, Reconstructive & Aesthetic Surgery, conducted at Nottingham Children's Hospital, shows positive results for Epiprotect®. The study highlights significant pain relief, safety, and quick and easy patient follow-ups. Involving 99 patients aged 0 - 18 years treated for partial-thickness burns, the study reveals that Epiprotect® has comparable acute healing outcomes to Biobrane® from Smith & Nephew, but with a significantly lower infection rate (2.6% compared to 16.4%).
"It is highly significant for S2Medical that high-quality studies like this confirm the benefits we have experienced during our journey to introduce Epiprotect® to the global market. That Epiprotect® now proves to reduce infection risks compared to one of the previously leading products is an enormously important finding, especially since infections in children can mean the difference between life and death," says the company's CEO, Petter Sivlér.
The company expects that the results will accelerate the commercialization of Epiprotect products, leading to increased royalty revenues and enhancing the potential for additional payments for Epiprotect.
This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-06-2024 10:32 CET.
Petter Sivlér - CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se
Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se
E-mail: ca@vatorsec.se